Scientists have identified a protein, Miro1, whose accumulation in skeletal muscle impairs the body's ability to respond to insulin, a central feature of type 2 diabetes. A study published in Nature Communications found that removing the protein restored insulin sensitivity in preclinical models and that a program of aerobic exercise reduced Miro1 levels in people with the condition. The discovery could point to potential new treatments for diabetes.
The research team studied Miro1 in laboratory cells, preclinical models and people with type 2 diabetes.
Miro1, a protein found on the outer membrane of mitochondria, was present at higher levels in the skeletal muscle of people with type 2 diabetes. Researchers believe excessive amounts may interfere with how muscles respond to insulin.
In the human component of the study, a randomized controlled trial involving participants with obesity and type 2 diabetes showed that an aerobic exercise regimen lowered Miro1 levels in muscle tissue. The drop corresponded with improvements in insulin sensitivity and the muscles' capacity to produce energy.
While the human trial demonstrated a strong correlation, the researchers established a causal link in preclinical experiments. Removing Miro1 from muscle cells restored their ability to respond to insulin, providing evidence that the protein is directly involved in driving insulin resistance.
Dr. John P. Kirwan, the study's senior author and now executive director of the OU Health Harold Hamm Diabetes Center, described Miro1 as a key part of the answer. "For the field, this is a new therapeutic target. For patients, it deepens our understanding of why exercise is so effective and opens a path toward treatments that could one day complement it," he said.
The researchers said scientists still need to establish whether directly targeting Miro1 can produce safe and effective treatments for people with type 2 diabetes. Kirwan plans to continue investigating the findings at the Harold Hamm Diabetes Center, combining laboratory experiments with studies involving people. “Ultimately, we are looking for cures, and we hope these recent findings could be part of the solution.”
Analysis
Why This Matters
- Type 2 diabetes is marked by insulin resistance, whose molecular causes have remained frustratingly unclear. This study provides a specific target, Miro1, for drug development.
- The research offers a molecular explanation for the benefits of exercise on blood sugar control, validating the mechanism through which physical activity works.
- It opens a clear path for developing therapies that could mimic or enhance the insulin-sensitising effects of exercise.
Background
Type 2 diabetes is characterised by insulin resistance, where the body's cells do not respond properly to insulin. Skeletal muscle is a major site of glucose disposal, making its insulin responsiveness critical for overall blood sugar regulation. The molecular drivers of this resistance have remained frustratingly unclear, leaving a gap in treatment options beyond lifestyle modification and existing drugs.
Key Perspectives
Dr. John P. Kirwan, senior author: Describes Miro1 as a key part of the answer that provides a new therapeutic target for the field and deepens understanding of why exercise is effective for patients.
Dr. Jennifer Rood, Pennington Biomedical: Emphasises the value of an integrated approach, connecting fundamental discoveries about muscle function with clinical research and public health benefits for people with type 2 diabetes.
What to Watch
- Whether Kirwan's laboratory can develop a drug or molecule that safely targets Miro1 in humans.
- If other research groups replicate the Miro1 finding in other insulin-resistant tissues.
- The potential for new clinical trials measuring Miro1 levels as a biomarker for insulin sensitivity and response to exercise.
Checked
10 claims in this story checked against 1 source: 7 supported.
Show each claim
- SupportedResearchers link Miro1 to insulin resistance in type 2 diabetes.Latest Science News -- ScienceDaily: “The findings were published in Nature Communications and could help researchers better understand the biological processes behind insulin resistance, a central feature of Type 2 diabetes.”
- SupportedExercise reduces Miro1 levels, offering a potential new target for treatments.Latest Science News -- ScienceDaily: “Scientists have identified a protein linked to Type 2 diabetes that exercise can reduce, opening the door to potentially powerful new treatments for insulin resistance.”
- Partly supportedMiro1 accumulation in skeletal muscle impairs the body's ability to respond to insulin.Latest Science News -- ScienceDaily: “The results showed that Miro1 buildup impaired the muscles' response to insulin.”
- Partly supportedRemoving Miro1 from muscle cells restored insulin sensitivity in preclinical models.Latest Science News -- ScienceDaily: “In preclinical experiments, scientists discovered that removing Miro1 restored the muscles' response to insulin.”
- SupportedAn aerobic exercise program reduced Miro1 levels in people with type 2 diabetes.Latest Science News -- ScienceDaily: “People assigned to the exercise group experienced a decline in Miro1 levels in their muscles.”
- Partly supportedThe human trial showed a strong correlation between reduced Miro1 and improved insulin sensitivity.Latest Science News -- ScienceDaily: “These changes occurred alongside improvements in insulin sensitivity and the muscles' capacity to produce energy.”
- SupportedThe study was a randomized controlled trial involving participants with obesity and type 2 diabetes.Latest Science News -- ScienceDaily: “In a randomized controlled trial involving participants with obesity and Type 2 diabetes, they compared the effects of aerobic exercise with those of standard medical care.”
- SupportedKirwan said: “For the field, this is a new therapeutic target. For patients, it deepens our understanding of why exercise is so effective and opens a path toward treatments that could one day complement it.”Latest Science News -- ScienceDaily: “For the field, this is a new therapeutic target. For patients, it deepens our understanding of why exercise is so effective and opens a path toward treatments that could one day complement it,” said Dr. John P. Kirwan, the study’s senior author.”
- SupportedKirwan is the study's senior author and became executive director of the OU Health Harold Hamm Diabetes Center.Latest Science News -- ScienceDaily: “Kirwan recently became executive director of the OU Health Harold Hamm Diabetes Center at the University of Oklahoma.”
- SupportedKirwan said, “Ultimately, we are looking for cures, and we hope these recent findings could be part of the solution.”Latest Science News -- ScienceDaily: ““Ultimately, we are looking for cures, and we hope these recent findings could be part of the solution.””